Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

armasset.com">kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Clevudine will not demonstrate any additive antiviral benefit in combination with tenofovir in the head-to-head study, the risk that Clevudine will not demonstrate superiority over Hepsera in Clevudine's ongoing Phase 3 registration study, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

Viread and Hepsera are registered trademarks of Gilead Sciences, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 ... some of our Medicare resources and continue highlighting the success of the prescription drug ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ) today ... managing director of Warburg Pincus LLC, to the Amgen Board ... Fred Hassan and the deep, global experience he ... Robert A. Bradway , chairman and chief executive officer ... will serve Amgen well." Mr. Hassan has been ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... announces that a new market research report is ... Triple Analysis: Leukemia, Prostate Cancer and Apoptosis ... This triple analysis focuses on cancer drug development ... by the mechanism/target/effect of Apoptosis. Each of these ...
... SILVER SPRING, Md., May 3, 2011 The U.S. ... Commission (FTC) today announced a joint effort to remove ... treat, cure, and prevent sexually transmitted diseases (STDs). Among ... Viruxo, C-Cure, and Never An Outbreak. (Logo: ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 2Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 3Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 4FDA, FTC Act To Remove Fraudulent STD Products From The Market 2FDA, FTC Act To Remove Fraudulent STD Products From The Market 3
(Date:7/30/2015)... ... July 30, 2015 , ... The connection between a healthy head of hair and a feeling ... a full head of hair can have a devastating impact on the daily life of ... the work place, the consequences of hair loss are not to be taken lightly. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual intended to symbolize a ... Treatment Center have created an addiction graveyard. Sharing this with the public comes at ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he ...
(Date:7/30/2015)... ... , ... The American Telemedicine Association (ATA) is seeking presentations ... on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 attendees ... 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s most ...
(Date:7/30/2015)... ... 2015 , ... " DevExpress ” was featured on NewsWatch ... medium, and large businesses making an impact in their industry. Susan Bridges, a ... with viewers how DevExpress has provided software development tools that have helped app ...
(Date:7/30/2015)... (PRWEB) , ... July 30, ... ... released a video, “Beachside Nursing Center,” to announce its position as one ... ratings. Beachside's administrator and staff members support the CMS rating system, which ...
Breaking Medicine News(10 mins):Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2
... begun to help,United Healthcare Workers-West members fight unprecedented ... International Union President and,Secretary-Treasurer., "A Salute to ... Health Care Workers-West and their President, Sal Rosselli, ... at the Julia Morgan,Ballroom, Merchants Exchange Building, 465 ...
... Lasers Limited (ASX:,ELX), a global leader in the ... today announced the six-month clinical study results,for the ... annual meeting of the American Academy of Ophthalmology.,The ... FRCPath,FRCOphth (Hons), of St. Thomas, Hospital, London, under ...
... E, C did little to protect healthy men, either ... studies released Sunday cast doubt on the cardiac benefits ... Japanese researchers found that low-dose aspirin did not reduce ... 2 diabetes. , Second, Harvard researchers concluded that neither ...
... to foil a tumor from generating blood vessels to feed ... creating drugs aimed at stopping a key vessel growth-promoting protein. ... Researchers at the Moores Cancer Center at the University of ... that blocking that protein target, called VEGF, or vascular endothelial ...
... Room #283-285, Ernest N. Morial Convention Center) , A team ... five key proteins out of thousands secreted into blood draining ... certain quantities form the basis of a far more accurate ... attack in people with severely reduced blood flow, or ischemia. ...
... less likely than Caucasian patients to undergo coronary ... successful angioplasty, a type of percutaneous coronary intervention ... Hispanics also had a trend toward lower ... and bypass surgery, according to a study presented ...
Cached Medicine News:Health News:Health Care Workers Get Help Fighting Unprecedented Attacks from Service Employee International Union Leadership 2Health News:Ellex Announces Six-Month Results on Retina Regeneration Therapy 2Health News:Ellex Announces Six-Month Results on Retina Regeneration Therapy 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Cancer drugs my build and not tear down blood vessels 2Health News:Cancer drugs my build and not tear down blood vessels 3Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 2Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 3Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 4Health News:Hispanics less likely to have repeat revascularizations 1 year after angioplasty 2
... Immunoassay Control is a ... designed to complement the ... Immunoassay Plus Controls. This ... to include more complex ...
Liquichek Hematology-8 Control is a whole blood hematology control with extended stability for non-differential analyzers....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: